Skip to main content

Table 2 Results of the multivariable cox model for progression-free survival

From: Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis

Variable

Risk category

Beta

HR

95% CI

p-value

Sex

Male/female

−0.06

0.95

(0.85-1.05)

0.310

Age

>65 years/<65 years

−0.03

0.97

(0.87-1.08)

0.580

Site of primary tumour

Rectum/colon

0.08

1.08

(0.97-1.20)

0.170

Primarily metastatic

M1/M0

0.11

1.12

(1.00-1.25)

0.057

Number of metastatic sites

2/1

0.33

1.39

(1.24-1.56)

<0.001

 

3 and more/1

0.51

1.66

(1.41-1.95)

<0.001

CT regimen

XELOX/FOLFOX

−0.05

0.95

(0.84-1.08)

0.400